Literature DB >> 27888017

Circulating CXCR5+CD4+ T cells assist in the survival and growth of primary diffuse large B cell lymphoma cells through interleukin 10 pathway.

Zhanshan Cha1, Guangfang Qian2, Yan Zang1, Haihui Gu1, Yanyan Huang1, Lishuang Zhu1, Jinqi Li1, Yang Liu1, Xiaohua Tu1, Haihan Song3, Baohua Qian4.   

Abstract

Diffuse large B cell lymphoma (DLBCL) is a common and aggressive cancer caused by the malignant transformation of B cells. Although it has been established that the follicular helper T (Tfh) cells play a central role in B cell development, little information is available on their involvement in DLBCL pathogenesis. We studied the role of the peripheral Tfh equivalent, the CXCR5+ CD4+ T cells, in DLBCL. Data showed that compared to CXCR5- CD4+ T cells, CXCR5+ CD4+ T cells were significantly more effective at promoting the proliferation as well as inhibiting the apoptosis of primary autologous DLBCL tumor cells. Surprisingly, we found that at equal cell numbers, CXCR5+ CD4+ T cells in DLBCL patients secreted significantly less interleukin (IL)-21 than CXCR5- CD4+ T cells, while the level of IL-10 secretion was significant elevated in the CXCR5+ compartment compared to the CXCR5- compartment. Neutralization of IL-10 in the primary DLBCL-CXCR5+ CD4+ T cell coculture compromised the CXCR5+ CD4+ T cell-mediated pro-tumor effects, in a manner that was dependent on the concentration of anti-IL-10 antibodies. The CXCR5+ compartment also contained significantly lower frequencies of cytotoxic CD4+ T cells than the CXCR5- compartment. In conclusion, our investigations discovered a previously unknown pro-tumor role of CXCR5-expressing circulating CD4+ T cells, which assisted the survival and proliferation of primary DLBCL cells through IL-10.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diffuse large B cell lymphoma; Follicular helper T cell; Interleukin 10

Mesh:

Substances:

Year:  2016        PMID: 27888017     DOI: 10.1016/j.yexcr.2016.11.017

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

1.  Distribution of circulating follicular helper T cells and expression of interleukin-21 and chemokine C-X-C ligand 13 in gastric cancer.

Authors:  Xinying Meng; Xinjuan Yu; Quanjiang Dong; Xiaona Xu; Jinghua Li; Qianqian Xu; Jian Ma; Changhong Zhou
Journal:  Oncol Lett       Date:  2018-07-10       Impact factor: 2.967

2.  CXCL13 Signaling in the Tumor Microenvironment.

Authors:  Muzammal Hussain; Jinsong Liu; Gui-Zhen Wang; Guang-Biao Zhou
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Circulating Tfh1 (cTfh1) cell numbers and PD1 expression are elevated in low-grade B-cell non-Hodgkin's lymphoma and cTfh gene expression is perturbed in marginal zone lymphoma.

Authors:  Elliot T Byford; Matthew Carr; Eleni Ladikou; Matthew J Ahearne; Simon D Wagner
Journal:  PLoS One       Date:  2018-01-02       Impact factor: 3.240

Review 4.  Control of Germinal Center Responses by T-Follicular Regulatory Cells.

Authors:  James B Wing; Murat Tekgüç; Shimon Sakaguchi
Journal:  Front Immunol       Date:  2018-08-24       Impact factor: 7.561

5.  CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin's lymphoma and tumor-supportive follicular T helper cells.

Authors:  Mario Bunse; Janina Pfeilschifter; Julia Bluhm; Maria Zschummel; Jara J Joedicke; Anthea Wirges; Helen Stark; Vivien Kretschmer; Markus Chmielewski; Wolfgang Uckert; Hinrich Abken; Jörg Westermann; Armin Rehm; Uta E Höpken
Journal:  Nat Commun       Date:  2021-01-11       Impact factor: 14.919

6.  Combined cellular and soluble mediator analysis for improved diagnosis of vitreoretinal lymphoma.

Authors:  Joeri de Hoog; Willem A Dik; Lucy Lu; Kim C Heezen; Josianne C Ten Berge; Sigrid M A Swagemakers; Peter J van der Spek; Jacques J M van Dongen; Vincent H J van der Velden; Aniki Rothova; Anton W Langerak
Journal:  Acta Ophthalmol       Date:  2019-01-27       Impact factor: 3.761

Review 7.  Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer.

Authors:  Ching-Hung Hsieh; Cheng-Zhe Jian; Liang-In Lin; Guan-Sian Low; Ping-Yun Ou; Chiun Hsu; Da-Liang Ou
Journal:  Cancers (Basel)       Date:  2022-01-07       Impact factor: 6.639

Review 8.  CXCL13 in Cancer and Other Diseases: Biological Functions, Clinical Significance, and Therapeutic Opportunities.

Authors:  San-Hui Gao; Sheng-Zhi Liu; Gui-Zhen Wang; Guang-Biao Zhou
Journal:  Life (Basel)       Date:  2021-11-23

Review 9.  Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics.

Authors:  Daniel J García-Domínguez; Lourdes Hontecillas-Prieto; Natalia Palazón-Carrión; Carlos Jiménez-Cortegana; Víctor Sánchez-Margalet; Luis de la Cruz-Merino
Journal:  Cancers (Basel)       Date:  2022-03-13       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.